Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
Sign Up to like & getrecommendations! Published in 2020 at "EJNMMI Research"
DOI: 10.1186/s13550-020-00637-x
Abstract: Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed… read more here.
Keywords: dota miltuximab; antibody; miltuximab; 177lu dota ... See more keywords